These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30238620)

  • 41. Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay.
    Tang S; Chen A; Zhou X; Zeng L; Liu M; Wang X
    Toxicol Lett; 2017 Nov; 281():74-83. PubMed ID: 28941798
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.
    Lieu C; Shi J; Donat F; Van Horn R; Brian W; Newton J; Delbressine L; Vos R
    Clin Pharmacokinet; 2002; 41 Suppl 2():19-26. PubMed ID: 12383041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450.
    McCormick A; Swaisland H; Reddy VP; Learoyd M; Scarfe G
    Xenobiotica; 2018 Jun; 48(6):555-564. PubMed ID: 28657402
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Screening of ten cytochrome P450 enzyme activities with 12 probe substrates in human liver microsomes using cocktail incubation and liquid chromatography-tandem mass spectrometry.
    Kim HJ; Lee H; Ji HK; Lee T; Liu KH
    Biopharm Drug Dispos; 2019 Apr; 40(3-4):101-111. PubMed ID: 30730576
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study.
    Basińska-Ziobroń A; Daniel WA; Wójcikowski J
    Pharmacol Rep; 2015 Dec; 67(6):1178-82. PubMed ID: 26481538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism.
    Miyazaki H; Ikeda Y; Sakurai O; Miyake T; Tsubota R; Okabe J; Kuroda M; Hisada Y; Yanagida T; Yoneda H; Tsukumo Y; Tokunaga S; Kawata T; Ohashi R; Fukuda H; Kojima K; Kannami A; Kifuji T; Sato N; Idei A; Iguchi T; Sakairi T; Moritani Y
    Bioorg Med Chem Lett; 2018 Jun; 28(11):2055-2060. PubMed ID: 29724589
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment.
    Gong Y; Haque S; Chowdhury P; Cory TJ; Kodidela S; Yallapu MM; Norwood JM; Kumar S
    Expert Opin Drug Metab Toxicol; 2019 May; 15(5):417-427. PubMed ID: 30951643
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of a substrate cocktail approach in the assessment of cytochrome P450 induction using cultured human hepatocytes.
    Pelletier RD; Lai WG; Wong YN
    J Biomol Screen; 2013 Feb; 18(2):199-210. PubMed ID: 23071008
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.
    Rhodes SP; Otten JN; Hingorani GP; Hartley DP; Franklin RB
    J Pharmacol Toxicol Methods; 2011; 63(3):223-6. PubMed ID: 21111054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.
    Kim HJ; Kim IS; Rehman SU; Ha SK; Nakamura K; Yoo HH
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1826-1830. PubMed ID: 28274629
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-Throughput Cytochrome P450 Cocktail Inhibition Assay for Assessing Drug-Drug and Drug-Botanical Interactions.
    Li G; Huang K; Nikolic D; van Breemen RB
    Drug Metab Dispos; 2015 Nov; 43(11):1670-8. PubMed ID: 26285764
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simultaneous determination of multiple CYP inhibition constants using a cocktail-probe approach.
    Zientek M; Youdim K
    Methods Mol Biol; 2013; 987():11-23. PubMed ID: 23475664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters.
    Ramsden D; Wu JT; Zerler B; Iqbal S; Jiang J; Clausen V; Aluri K; Gu Y; Dennin S; Kim J; Chong S
    Drug Metab Dispos; 2019 Oct; 47(10):1183-1194. PubMed ID: 31270142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
    Wu Y; Chitranshi P; Loukotková L; Gamboa da Costa G; Beland FA; Zhang J; Fang JL
    Arch Toxicol; 2017 Jun; 91(6):2405-2423. PubMed ID: 27896399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
    Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
    Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of Huperzine A.
    Lin PP; Li XN; Yuan F; Chen WL; Yang MJ; Xu HR
    Biochem Biophys Res Commun; 2016 Nov; 480(2):248-253. PubMed ID: 27751854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
    Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
    Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of the In Vitro Inhibitory Potential of the Oligonucleotide Imetelstat on Human Cytochrome P450 Enzymes with Predictions of In Vivo Drug-Drug Interactions.
    Kazmi F; Sensenhauser C; Greway T
    Drug Metab Dispos; 2019 Jan; 47(1):9-14. PubMed ID: 30389730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
    Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
    Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
    Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.